CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE
Clinical safety rating: caution
No significant drug interactions Topical use only excessive use can lead to hypercalcemia.
Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors (VDR) and suppresses keratinocyte proliferation while inducing differentiation. Betamethasone dipropionate is a potent corticosteroid that binds to glucocorticoid receptors, inhibiting pro-inflammatory mediators and reducing inflammation, pruritus, and vasodilation.
| Metabolism | Calcipotriene: hepatic metabolism via CYP24A1 and other enzymes; betamethasone dipropionate: mainly hepatic metabolism via CYP3A4 to various inactive metabolites. |
| Excretion | Calcipotriene: negligible systemic absorption; absorbed fraction undergoes hepatic metabolism and is excreted in feces (approx. 70%) and urine (approx. 20%). Betamethasone dipropionate: absorbed dose metabolized in liver, metabolites excreted primarily in urine (60-70%) and feces (20-30%). |
| Half-life | Calcipotriene: not applicable due to minimal systemic exposure. Betamethasone dipropionate: terminal half-life of betamethasone after topical application is approximately 5-6 hours. |
| Protein binding | Calcipotriene: >90% bound to plasma proteins (albumin). Betamethasone dipropionate: >90% bound to albumin. |
| Volume of Distribution | Calcipotriene: not clinically relevant due to low systemic absorption. Betamethasone dipropionate: Vd of betamethasone is approximately 1.4 L/kg, indicating wide distribution. |
| Bioavailability | Topical: systemic bioavailability of calcipotriene is <1% of applied dose; betamethasone dipropionate is <10% of applied dose through intact skin, but increases with inflamed skin. |
| Onset of Action | Topical: improvement typically noted within 2 weeks of twice-daily application. |
| Duration of Action | Duration of therapeutic effect after discontinuation not well-defined; continuous use recommended for maintenance. Clinical improvement often persists for several weeks after treatment cessation. |
| Molecular Weight | Calcipotriene: 412.6 Da; Betamethasone dipropionate: 504.6 Da |
Apply to affected areas once daily; maximum weekly dose should not exceed 100 g (calcipotriene 0.005% and betamethasone dipropionate 0.064% as combination ointment or foam).
| Dosage form | SUSPENSION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment; use with caution. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | Safety and efficacy in pediatric patients (age <12 years) have not been established. For patients 12–17 years, dosing is same as adult; maximum weekly dose not to exceed 60 g per week. |
| Geriatric use | No specific dose adjustment required; however, caution due to potential for increased skin atrophy, impaired renal/hepatic function, and concurrent medications. Use minimal effective amount. |
| 1st trimester | Use only if potential benefit justifies potential risk to fetus. Topical corticosteroids are generally avoided in first trimester due to limited safety data. Calcipotriene is a vitamin D analog; animal studies have shown fetal abnormalities at high doses. |
| 2nd trimester | Use with caution; avoid prolonged use on large areas. Systemic absorption of corticosteroids may cause fetal growth restriction. Calcipotriene is generally considered low risk topically. |
| 3rd trimester | Use cautiously, especially near term, due to risk of neonatal hypothalamic-pituitary-adrenal axis suppression from potent corticosteroids. Avoid application to large areas or prolonged use. |
Clinical note
No significant drug interactions Topical use only excessive use can lead to hypercalcemia.
| FDA category | Animal |
| Placental transfer | Corticosteroids cross the placenta; betamethasone is a potent corticosteroid with appreciable transfer. Calcipotriene has minimal systemic absorption, thus placental transfer is negligible. |
■ FDA Black Box Warning
No FDA boxed warning.
| Common Effects | Skin irritation |
| Serious Effects |
Hypersensitivity to calcipotriene, betamethasone dipropionate, or any component of the formulationKnown or suspected hypersensitivity to vitamin D or corticosteroidsUse on face, groin, or axillae (due to increased absorption and risk of atrophy)
| Precautions | May cause hypercalcemia due to calcipotriene absorption, especially when applied to large areas or occluded skin, Risk of hypothalamic-pituitary-adrenal (HPA) axis suppression from betamethasone, particularly with prolonged use, high potency, or large surface area, Local adverse reactions: skin atrophy, striae, telangiectasias, folliculitis, perioral dermatitis, allergic contact dermatitis, Not for use on face, groin, or axillae due to increased systemic absorption and skin atrophy risk, Caution in patients with renal impairment or hepatic impairment due to metabolic and excretory pathways, Do not use with occlusive dressings unless directed, May mask signs of infection and suppress immune response |
Loading safety data…
| Breastfeeding | Minimal systemic absorption after topical application; unlikely to cause adverse effects in the infant. Avoid application to breast or nipples to prevent infant ingestion. Use moisturizer after application to reduce transfer. Caution with large area/long-term use. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category C. Calcipotriene: No adequate human studies; animal studies show no teratogenicity at topical doses. Bethamethasone dipropionate: Corticosteroids can cause cleft palate, intrauterine growth restriction, and adrenal suppression in animal studies; human risk with topical use is low due to minimal systemic absorption. Avoid large areas or prolonged use in pregnancy. First trimester: theoretical risk but limited data. Second/third trimesters: low risk if used sparingly. |
| Fetal Monitoring | Monitor maternal blood glucose and blood pressure due to potential corticosteroid effects with extensive use. Observe fetal growth (ultrasound) if large areas treated. Monitor infant for signs of adrenal suppression if maternal use is prolonged or high-dose. |
| Fertility Effects | No human data on fertility effects. Animal studies with calcipotriene showed no impairment; betamethasone at high systemic doses may affect fertility. Topical use is unlikely to significantly impact fertility. |
| Food/Dietary | No clinically significant food-drug interactions. However, maintain adequate calcium and vitamin D intake as part of a balanced diet, but avoid excessive calcium supplementation due to potential hypercalcemia risk with extensive use. |
| Clinical Pearls | Avoid use on face, groin, axillae, or in intertriginous areas due to increased risk of corticosteroid side effects. Apply only to affected plaques; limit total weekly dose to ≤100 g or 60 mL to minimize risk of HPA axis suppression. Discontinue if skin atrophy, telangiectasias, or striae develop. Monitor for hypercalcemia in patients with extensive plaque psoriasis due to calcipotriene absorption. For patients with moderate-to-severe plaque psoriasis, consider sequential or rotational therapy to minimize long-term corticosteroid exposure. |
| Patient Advice | Apply a thin layer to psoriatic plaques once daily for up to 4 weeks as directed. · Do not use on the face, armpits, groin, or areas with skin folds. · Wash hands after application unless treating hands. · Avoid contact with eyes and mucous membranes. · Do not use occlusive dressings (e.g., bandages, wraps) over the treated area. · Inform your doctor if you develop severe skin irritation, signs of skin infection, or if psoriasis worsens. · Do not use more than the prescribed amount or for longer than recommended. |